Korea’s Government-Funded Venture into Oncology
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
Address: 18th Floor, Hanjin Main Bld, 118, Namdaemunno-2-ga, Seoul,Republic of Korea
Tel: +82 2 772 4000
With more than thirty years of experience as one of Republic of Korea’s premiere full-service law firms, Lee & Ko has a widely recognized and long-established record of excellence in providing expert legal advice and representation to its diverse clientele in domestic and international matters involving all areas of legal practice. ith a wealth of experience in virtually all aspects of corporate law practice, Lee & Ko continues to be a highly regarded leader among Republic of Korean law firms in providing excellent legal services and creative approaches to both domestic and foreign clients doing business in or with Republic of Korea. With some of Republic of Korea’s most experienced and capable corporate law practitioners among its partners and associates, Lee & Ko’s clients receive the highest quality, the most efficient, and the most innovative legal assistance available. Lee & Ko has a distinguished and well-deserved reputation for consistently providing timely, up-to-date, accurate and reliable legal assistance with all manner of corporate legal matters, including incorporation and registration, corporate governance issues and the issuance of corporate securities.
In addition, Lee & Ko has one of Republic of Korea’s most capable, versatile and extensive legal practices in domestic and cross-border mergers and acquisitions. Lee & Ko has served as key legal counsel for innumerable foreign and domestic clients in connection with a broad range of highly complex and sensitive transactions, particularly in recent decades as the Republic of Korean corporate landscape has become more international and complex.
National OncoVenture (NOV) is Korea’s Ministry of Health and Welfare funded oncology drug development program to nurture oncology innovation in the country. To maintain high access and limit costs of…
Seung-Kyou Lee, vice-president of Korea Bio gives his assessment on the current landscape for biotech firms in Korea. He also discusses Korea Bio’s programme to create a further 1000 biotech…
Young-Whan Park, president of National OncoVenture, discusses their programme to support oncology drug development in South Korea, with a view to discovering and producing a globally competitive, Korean-made oncology medicine.…
Christoph Heider, president of the European Chamber of Commerce in Korea (ECCK), discusses the organization, the need for the modernization of the Europe-South Korea Free Trade Agreement, and the future…
Southeast Asia’s notoriously strict anti-cannabis laws could be set to relax dramatically as South Korea becomes the first country in the region to legalise cannabis for medicinal use. This…
Sunyoung Kim, CEO and founder of ViroMed, reveals his strategy for conquering the US market and the feasibility of his ambitions for ViroMed to become the biotech company with the…
In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of…
Professor Dukgeun Ahn of Seoul National University, trade policy advisor to the Ministry of Health offers his insights into the current policies towards the healthcare industry in Korea, and the…
South Korea’s proposed Moon Jae-In Care has been subject to both praise and protest this year. President Moon Jae-in’s plan dubbed “Moon Care” will be implemented in stages throughout 2022…
Jongmoon Kim, CEO of ToolGen discusses the potential for their CRISPR technology to revolutionize not only therapy for genetic illnesses, but also agriculture. Kim explains his move from information technology…
JungTae Park, senior managing director of KoBIA (Korea Biomedicine Industry Association), describes the achievements of the association as a bridge between industry and government. He also highlights the potential of…
Jia Liu, CEO of DreamCIS, a Korean CRO, part of the Chinese company Tigermed, talks about her vision for DreamCIS to be “the CRO everybody wants to work with”. Liu…
See our Cookie Privacy Policy Here
